Ankylosing Spondylitis Market Size & Outlook, 2026-2034

Ankylosing Spondylitis Market Overview

The global ankylosing spondylitis market size is estimated at USD 6.64 billion in 2025 and is projected to reach USD 11.84 billion in 2034, growing at a CAGR of 6.68% during the forecast period. Remarkable growth of the market is due to the rising transition toward targeted biologics and expanded adoption of early diagnosis pathways that drive stronger treatment initiation rates.

Key Market Trends & Insights

• North America held a dominant share of the global market, accounting for 58.24% share in 2025.
• The Asia Pacific region is growing at the fastest pace, with a CAGR of 8.68%.
• Based on Drug Class, the TNF inhibitors segment dominated the market with 59.81% share.
• Based on Disease Stage, the moderate ankylosing spondylitis segment dominated the market with a 49.21% share.
• Based on the Diagnostic Method, the MRI segment dominated the market with a 41.21% share.
• Based on the Distribution Channel, the Hospital Pharmacy segment dominated the market with 48.99%.
• The U.S. dominates the global ankylosing spondylitis market, valued at USD 3.29 billion in 2024 and reaching USD 3.49 billion in 2025.

Graph: U.S. Market Revenue Forecast (2022 – 2034)

Source: Straits Research

Market Size & Forecast

• 2025 Market Size: USD 6.64 billion
• 2034 Projected Market Size: USD 11.84 billion
• CAGR (2025 to 2034): 6.68%
• Dominating Region: North America
• Fastest-Growing Region: Asia Pacific

The ankylosing spondylitis market encompasses the ecosystem of diagnostic, therapeutic, and distribution pathways involved in identifying and treating this chronic inflammatory spinal disorder. The market includes a full range of drug classes, from non-steroidal anti-inflammatory drugs used for early symptom relief to advanced TNF inhibitor therapies such as Humira, Simponi, Remicade, Enbrel, Cimzia, and other agents that target persistent axial inflammation, along with additional treatment categories used in broader disease management. Patient populations span early stage, moderate, and severe or advanced ankylosing spondylitis, each requiring distinct treatment strategies and monitoring approaches.

Diagnosis is supported by multiple modalities, including MRI for early inflammatory detection, X-ray radiography for structural assessment, laboratory biomarkers such as CRP and ESR, HLA B27 genetic testing, and digital spine monitoring tools that track functional change over time. The market reaches patients through diverse distribution channels, including hospital pharmacies for biologics, retail pharmacies for oral and supportive therapies, and other outlets that support ongoing access across various care settings.

Latest Market Trends

Shift from Symptom-Oriented Consultations to Progression-Focused Monitoring Pathways

The market transitions from consultations centered on short-term pain management toward monitoring frameworks that track structural and inflammatory progression over extended periods. Rheumatology units increasingly rely on serial assessment tools that capture spinal mobility changes, morning stiffness duration, and functional decline patterns. This shift promotes structured long-term care plans where treatment selection is guided by progression indicators rather than isolated symptom episodes. As practices adopt these pathways, clinicians gain clearer visibility into cumulative disease impact, strengthening early adjustment of therapeutic strategies.

Shift from Conventional Clinic-Based Follow-Up to Continuous Digital Engagement Models

The market progresses from episodic in-person visits toward platforms that sustain communication between patients and rheumatology teams throughout the treatment cycle. Digital check-in systems, mobility tracking apps, and virtual symptom diaries create continuous data streams that reflect day-to-day experience rather than occasional clinic reports. This shift enhances adherence to treatment schedules and supports timely physician intervention when disease activity fluctuates. As digital engagement becomes embedded in routine care, treatment plans evolve with greater precision and responsiveness.

To get more insights about this report Download Free Sample Report

Market Driver

Expanding Transition Toward Personalized Treatment Sequencing

Growth is driven by rising adoption of treatment sequences that align with individual disease activity patterns, genetic markers, and therapeutic response histories. Rheumatology specialists increasingly tailor interventions based on patient-specific trajectories rather than uniform stepwise protocols. This advancement supports the earlier introduction of advanced therapies when traditional agents provide limited improvement. Personalized sequencing establishes clearer value for targeted treatments and elevates long-term disease management outcomes, contributing to stronger market momentum.

Market Restraint

Variation in Access to Advanced Immunology Diagnostics Across Treatment Networks

The market encounters restraint due to uneven availability of advanced immunology diagnostics that support refined classification of axial inflammatory disorders. Smaller facilities encounter delays in obtaining specialized assessments, which creates longer transition periods between initial consultation and initiation of targeted therapies. Inconsistent access to detailed diagnostics slows adoption of precision-driven treatment strategies and contributes to gaps in patient evaluation across regional networks.

Market Opportunity

Rising Integration of Biomarker-Based Prognostic Platforms in Clinical Pathways

A broad opportunity emerges as research groups and clinical centers introduce biomarker-driven platforms that forecast disease progression, treatment response, and flare probability. These platforms incorporate serum markers, genetic profiles, and longitudinal mobility data to create predictive models used during clinical decision-making. Integration of prognostic tools encourages earlier therapeutic adjustments and stronger alignment between patient conditions and treatment plans. As adoption expands across academic hospitals and large rheumatology networks, these platforms create fresh value pathways within the ankylosing spondylitis market.

Regional Analysis

North America holds a leading position in the ankylosing spondylitis market with 58.24% share due to strong utilization of biologics, established rheumatology networks, and wide access to advanced imaging for axial inflammation assessment. The region benefits from extensive reimbursement pathways, broad participation in long-term immunology registries, and mature distribution systems that support continuous therapy availability across specialty clinics and hospital pharmacies. Growing preference for treatment protocols aligned with updated rheumatology guidelines further strengthens therapeutic adoption across the region.

The U.S. ankylosing spondylitis market expands through nationwide rollouts of advanced biologics and biosimilars, increased screening across rheumatology practices, and broad distribution of targeted therapies through specialty pharmacies. Academic medical centers enhance referral pathways for early axial spondyloarthritis detection, creating a structured care continuum that improves access to treatment across urban and semi-urban regions.

Asia Pacific Market Insights

Asia Pacific emerges as the fastest-growing region with a CAGR of 8.68% driven by rising diagnosis rates of inflammatory spinal disorders, growing access to MRI-based evaluation, and wider availability of biologic and biosimilar therapies in metropolitan healthcare systems. Expansion of rheumatology departments in China, India, Japan, and South Korea supports broader adoption of standardized management programs across large hospital clusters. Increasing awareness programs for chronic inflammatory back pain encourage early consultation and consistent follow-up care.

The Chinese ankylosing spondylitis market progresses through national healthcare upgrades, expansion of specialist rheumatology clinics, and greater domestic manufacturing of biologic therapies. Tertiary hospitals continue to add advanced imaging suites and structured axial spondyloarthritis evaluation pathways, increasing access to timely diagnosis across major provinces.

Pie Chart: Regional Market Share, 2025

Source: Straits Research

Europe Market Insights

Europe drives market advancement through coordinated clinical frameworks for axial spondyloarthritis management, a broad network of specialist centers, and increasing incorporation of digital platforms that support patient monitoring and treatment continuity. Regional collaborations among research institutes enhance real-world data generation, while the rising adoption of biosimilars improves accessibility across several countries. Structured national guidelines ensure consistent treatment pathways across member states.

The UK ankylosing spondylitis market grows through investments in community-based rheumatology units, expansion of specialist outpatient centers, and wider implementation of early referral frameworks for chronic back pain. Academic and clinical collaborations refine care models that support the timely initiation of biologics across regional hospitals.

Middle East and Africa Market Insights

The Middle East and Africa region experiences steady progression supported by increasing adoption of biologic therapies, expansion of private rheumatology clinics, and growing integration of imaging-based evaluation across Gulf nations. Rising medical tourism and strengthened hospital infrastructure contribute to wider access to axial spondyloarthritis treatment options across urban centers.

The South African ankylosing spondylitis market advances through partnerships between teaching hospitals and global pharmaceutical firms, expanding the availability of biologics within public and private facilities. Local healthcare providers introduce new training initiatives for rheumatology professionals, improving timely diagnosis and structured management of axial inflammatory disorders.

Latin America Market Insights

Latin America expands its ankylosing spondylitis market through rising referrals to rheumatology departments, broader use of biologics in urban medical institutions, and the growth of private healthcare networks that offer comprehensive treatment programs. Enhanced access to diagnostic imaging across regional hospitals supports early identification of axial inflammation and supports sustained therapy adoption.

The Argentine ankylosing spondylitis market strengthens through national awareness campaigns on chronic spinal inflammation, expansion of rheumatology units in public hospitals, and new collaborations supporting clinical research in inflammatory diseases. Healthcare institutions continue to adopt advanced imaging and therapeutic regimens, enabling wider access to treatment across the country.

Drug Class Insights

The TNF inhibitors segment dominates the market with 59.81%, supported by wide adoption across rheumatology practices for long-term disease control and sustained presence of established brands. Broad clinical familiarity and consistent treatment initiation within specialty centers reinforce the leadership of this class.

The non-steroidal anti-inflammatory drug segment records the fastest growth at 7.12%, driven by rising early-stage prescriptions and broader use as first-line therapy for chronic inflammatory back pain. Continued uptake among newly diagnosed patients strengthens momentum for this medication class.

Disease Stage Insights

The moderate ankylosing spondylitis segment dominates its category with 49.21%, driven by large patient volumes transitioning to advanced therapeutic regimens and increased treatment initiation within this group. Expanded access to specialty care supports the strong presence of this stage in the overall market share.

The early-stage ankylosing spondylitis segment posts the fastest growth at 7.86%, supported by rising awareness of axial symptoms and increased referrals for evaluation before structural progression. Broader recognition of early inflammatory indicators accelerates growth within this category.

Diagnostic Method Insights

The MRI segment dominates with 41.21%, supported by its role in detecting early inflammatory changes and guiding timely treatment decisions across specialized centers. Broader availability of advanced imaging within large facilities sustains the leadership of this segment.

The digital spine monitoring tools segment records the fastest growth at 7.34%, driven by rising adoption of technology-based disease tracking systems and increased use of digital assessment platforms in routine follow-up care. Greater integration of remote monitoring supports the expansion of this segment.

Distribution Channel Insights

The hospital pharmacy segment dominates with 48.99%, supported by continuous distribution of biologics, structured treatment protocols, and growing patient movement through specialty clinics linked to hospital networks. Strong alignment with rheumatology services sustains dominance in this channel.

The retail pharmacy segment records the fastest growth at 7.98%, driven by increasing availability of oral therapies, wider prescription refill volumes, and expanding patient preference for convenient outpatient access. Broader placement of ankylosing spondylitis medications across community pharmacies reinforces growth in this channel.

Segmentation by Distribution Channel in 2025 (%)

Source: Straits Research

Competitive Landscape

The ankylosing spondylitis market is moderately consolidated, with large originator pharmaceutical companies, biosimilar manufacturers, specialty biotechs, and contract development and manufacturing organizations shaping a competitive environment.

UCB S.A.: An Emerging Market Player

• UCB S.A. strengthened its position by expanding its immunology franchise through clinical development programs and real world evidence initiatives. The company advanced engagement with rheumatology specialists and enhanced patient support pathways, which sustained treatment uptake across developed markets. UCB’s continued investment in targeted immunology assets created growth opportunities across ankylosing spondylitis and broader axial spondyloarthritis segments as global demand for differentiated therapies increased.

List of key players in Ankylosing Spondylitis Market

1. AbbVie Inc.
2. Novartis Pharmaceuticals Corporation
3. UCB S.A.
4. Amgen Inc.
5. Pfizer Inc.
6. Eli Lilly and Company
7. Janssen-Cilag Limited
8. Merck & Co., Inc.
9. Boehringer Ingelheim Pharmaceuticals, Inc. 
10. CELLTRION INC.
11. Samsung Bioepis
12. Reliance Life Sciences
13. Zydus Lifesciences Limited
14. Gilead Sciences, Inc. 
15. Hoffmann-La Roche Ltd
16. Others

To get more findings about this report Download Market Share

Strategic Initiatives

• April 2025: Biocad, together with the Russian National Research Medical University of Pirogov and the Institute of Bioorganic Chemistry, reported Seniprutug as a domestic drug for the treatment of ankylosing spondylitis. The drug was already registered earlier and was planned to reach patients across 45 Russian regions, with the ability to relieve symptoms and slow disease progression.

• March 2025: Pfizer, Inc. Canada announced that IXIFI, its infliximab biosimilar, would be available in Canada from April 1, 2025. Approved by Health Canada in December 2021, IXIFI covered multiple indications, including ankylosing spondylitis, rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and plaque psoriasis, expanding access to affordable biologics.